

George Ioannou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8041323/publications.pdf>

Version: 2024-02-01

151
papers

11,053
citations

26567

56
h-index

32761

100
g-index

155
all docs

155
docs citations

155
times ranked

13786
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1723-1738.e5.	2.4	12
2	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	2.4	15
3	Trends Over Time in the Risk of Adverse Outcomes Among Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Clinical Infectious Diseases</i> , 2022, 74, 416-426.	2.9	20
4	Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. <i>Hepatology Communications</i> , 2022, 6, 12-35.	2.0	80
5	Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol. <i>Hepatology Communications</i> , 2022, 6, 780-794.	2.0	28
6	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1289-1299.	3.6	26
7	Risk factors for adverse outcomes in emergency versus nonemergency open umbilical hernia repair and opportunities for elective repair in a national cohort of patients with cirrhosis. <i>Surgery</i> , 2022, 172, 184-192.	1.0	7
8	COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System. <i>Annals of Internal Medicine</i> , 2022, 175, 352-361.	2.0	41
9	Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system. <i>EClinicalMedicine</i> , 2022, 45, 101326.	3.2	29
10	The COVID-19 Pandemic Highlights Opportunities to Improve Hepatocellular Carcinoma Screening and Diagnosis in a National Health System. <i>American Journal of Gastroenterology</i> , 2022, 117, 678-684.	0.2	14
11	PM2.5 air pollution exposure and nonalcoholic fatty liver disease in the Nationwide Inpatient Sample. <i>Environmental Research</i> , 2022, 213, 113611.	3.7	22
12	Hepatocellular Carcinoma Risk Declines but Remains High Enough for Screening in the First 7 Years After Hepatitis C Virus Cure With Direct-Acting Antivirals in Patients With Cirrhosis or High Fibrosis-4 Score. <i>Gastroenterology</i> , 2022, 163, 1104-1106.e3.	0.6	7
13	Incidence and Risk Factors of Postoperative Mortality and Morbidity After Elective Versus Emergent Abdominal Surgery in a National Sample of 8193 Patients With Cirrhosis. <i>Annals of Surgery</i> , 2021, 274, e345-e354.	2.1	33
14	Impact of exposure to patients with COVID-19 on residents and fellows: an international survey of 1420 trainees. <i>Postgraduate Medical Journal</i> , 2021, 97, 706-715.	0.9	52
15	Risk Factors for Testing Positive for Severe Acute Respiratory Syndrome Coronavirus 2 in a National United States Healthcare System. <i>Clinical Infectious Diseases</i> , 2021, 73, e3085-e3094.	2.9	35
16	No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. <i>Gut</i> , 2021, 70, gutjnl-2019-319867.	6.1	24
17	Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2394-2406.	1.1	21
18	Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 850-859.	1.8	13

#	ARTICLE	IF	CITATIONS
19	HCC surveillance after SVR in patients with F3/F4 fibrosis. <i>Journal of Hepatology</i> , 2021, 74, 458-465.	1.8	86
20	Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality. <i>Hepatology</i> , 2021, 74, 322-335.	3.6	66
21	Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 73, 204-218.	3.6	83
22	BMI and Outcomes of SARS-CoV-2 Among US Veterans. <i>Obesity</i> , 2021, 29, 900-908.	1.5	28
23	Development of COVIDVax Model to Estimate the Risk of SARS-CoV-2-Related Death Among 7.6 Million US Veterans for Use in Vaccination Prioritization. <i>JAMA Network Open</i> , 2021, 4, e214347.	2.8	33
24	SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. <i>Contemporary Clinical Trials</i> , 2021, 104, 106367.	0.8	13
25	Editorial: is there a "precursor" HCC lesion and can it be detected by hepatobiliary contrast-enhanced magnetic resonance imaging?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 202-203.	1.9	0
26	Epidemiology and risk-stratification of NAFLD-associated HCC. <i>Journal of Hepatology</i> , 2021, 75, 1476-1484.	1.8	160
27	Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication. <i>Hepatology Communications</i> , 2021, 5, 1465-1468.	2.0	1
28	Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 411-415.	0.2	9
29	Associations Between Alcohol Use and Liver-Related Outcomes in a Large National Cohort of Patients With Cirrhosis. <i>Hepatology Communications</i> , 2021, 5, 2080-2095.	2.0	25
30	Changes in the associations of race and rurality with SARS-CoV-2 infection, mortality, and case fatality in the United States from February 2020 to March 2021: A population-based cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003807.	3.9	16
31	Factors associated with early receipt of COVID-19 vaccination and adherence to second dose in the Veterans Affairs healthcare system. <i>PLoS ONE</i> , 2021, 16, e0259696.	1.1	14
32	Adapted time-varying covariates Cox model for predicting future cirrhosis development performs well in a large hepatitis C cohort. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 347.	1.5	1
33	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 974-983.	2.4	16
34	Prevalence of Hepatitis B Virus Exposure in the Veterans Health Administration and Association With Military-Related Risk Factors. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 954-962.e6.	2.4	5
35	Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1197-1206.e7.	2.4	20
36	Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment. <i>Hepatology Communications</i> , 2020, 4, 314-324.	2.0	11

#	ARTICLE	IF	CITATIONS
37	Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 364-373.	1.9	22
38	Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 ⁶ -131 US Veterans With SARS-CoV-2 Infection. <i>JAMA Network Open</i> , 2020, 3, e2022310.	2.8	305
39	Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. <i>JAMA Network Open</i> , 2020, 3, e2015626.	2.8	75
40	Hepatitis C-Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1003.	3.8	17
41	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 19, 1992-1993.	2.4	0
42	Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach. <i>Metabolites</i> , 2020, 10, 168.	1.3	26
43	Exercise retards hepatocarcinogenesis in obese mice independently of weight control. <i>Journal of Hepatology</i> , 2020, 73, 140-148.	1.8	28
44	Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1717-1727.	1.9	13
45	Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals. <i>Hepatology Communications</i> , 2019, 3, 1124-1136.	2.0	11
46	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. <i>Gastroenterology</i> , 2019, 157, 1264-1278.e4.	0.6	252
47	Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 1510-1519.	2.0	66
48	Editorial: hepatocellular carcinoma in the absence of cirrhosis is a nightmare without solution. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1062-1063.	1.9	0
49	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 157, 1253-1263.e2.	0.6	131
50	A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma Initial, Maximum, Last Classification. <i>Liver Transplantation</i> , 2019, 25, 559-570.	1.3	7
51	Editorial: benefits of HCV eradication beyond the liver. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1364-1365.	1.9	0
52	Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. <i>Journal of Hepatology</i> , 2019, 71, 523-533.	1.8	124
53	No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 47-52.	0.8	7
54	Reply. <i>Gastroenterology</i> , 2019, 156, 1218-1220.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2019, 3, 776-791.	2.0	50
56	Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy. <i>Clinical Liver Disease</i> , 2019, 13, 6-12.	1.0	16
57	For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective?. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1732-1735.	2.4	5
58	What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?. <i>Gastroenterology</i> , 2019, 156, 446-460.e2.	0.6	149
59	Machine learning models to predict disease progression among veterans with hepatitis C virus. <i>PLoS ONE</i> , 2019, 14, e0208141.	1.1	59
60	Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment". <i>Journal of Hepatology</i> , 2019, 70, 211-212.	1.8	0
61	Mouse models of non-alcoholic steatohepatitis: A reflection on recent literature. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1312-1320.	1.4	34
62	Genetic ablation of <i>Cyp8b1</i> preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 314, E418-E432.	1.8	22
63	Reply to: "Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything" and "More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations". <i>Journal of Hepatology</i> , 2018, 68, 219-220.	1.8	4
64	HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, 25-32.	1.8	393
65	Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. <i>PLoS ONE</i> , 2018, 13, e0204412.	1.1	77
66	The Impact of Direct-acting Antiviral Therapy for Hepatitis C on Hepatocellular Carcinoma Risk. <i>Current Hepatology Reports</i> , 2018, 17, 377-384.	0.4	14
67	Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. <i>Nature Communications</i> , 2018, 9, 4490.	5.8	135
68	No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 155, 1128-1139.e6.	0.6	80
69	Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. <i>Drug and Alcohol Dependence</i> , 2018, 188, 79-85.	1.6	21
70	Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. <i>Journal of Hepatology</i> , 2018, 69, 1088-1098.	1.8	119
71	Reply. <i>Hepatology</i> , 2017, 65, 2125-2126.	3.6	1
72	Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 32-39.	1.8	121

#	ARTICLE	IF	CITATIONS
73	Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1201-1212.	1.9	47
74	NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. <i>Journal of Hepatology</i> , 2017, 66, 1037-1046.	1.8	738
75	Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH. <i>Journal of Lipid Research</i> , 2017, 58, 1067-1079.	2.0	111
76	Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C. <i>Journal of Viral Hepatitis</i> , 2017, 24, 966-975.	1.0	18
77	Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17,487 patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 686-693.	0.8	50
78	Transplant-related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma. <i>Liver Transplantation</i> , 2017, 23, 652-662.	1.3	18
79	The selective peroxisome proliferator-activated receptor- δ agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. <i>Hepatology Communications</i> , 2017, 1, 663-674.	2.0	69
80	TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival. <i>Clinical Science</i> , 2017, 131, 2145-2159.	1.8	64
81	Disparities in Waitlist and Posttransplantation Outcomes in Liver Transplant Registrants and Recipients Aged 18 to 24 Years. <i>Transplantation</i> , 2017, 101, 1616-1627.	0.5	20
82	Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. <i>Diabetes Care</i> , 2017, 40, 1173-1180.	4.3	130
83	Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. <i>Obesity</i> , 2017, 25, 155-165.	1.5	40
84	The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. <i>Hepatology</i> , 2017, 65, 426-438.	3.6	68
85	Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. <i>PLoS ONE</i> , 2017, 12, e0189965.	1.1	35
86	Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients in the VA Healthcare System. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 667-675.	0.8	11
87	Sex difference in liver-related mortality and transplantation associated with dietary cholesterol in chronic hepatitis C virus infection. <i>British Journal of Nutrition</i> , 2016, 115, 193-201.	1.2	3
88	How can we improve prioritization for liver transplantation in patients with hepatocellular carcinoma?. <i>Liver Transplantation</i> , 2016, 22, 1321-1323.	1.3	2
89	Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. <i>Drug and Alcohol Dependence</i> , 2016, 169, 101-109.	1.6	58
90	Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. <i>Gastroenterology</i> , 2016, 151, 457-471.e5.	0.6	195

#	ARTICLE	IF	CITATIONS
91	Use of Antibiotics Among Patients With Cirrhosis and Upper Gastrointestinal Bleeding Is Associated With Reduced Mortality. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1629-1637.e1.	2.4	34
92	Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit. <i>Gastroenterology</i> , 2016, 150, 441-453.e6.	0.6	150
93	The Role of Cholesterol in the Pathogenesis of NASH. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 84-95.	3.1	347
94	Reply. <i>Gastroenterology</i> , 2016, 150, 535-537.	0.6	0
95	Association Between Transjugular Intrahepatic Portosystemic Shunt and Survival in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 118-123.	2.4	40
96	Obesity and diabetes accelerate hepatocarcinogenesis via hepatocyte proliferation independent of NF- κ B or Akt/mTORC1. <i>Journal of Clinical and Translational Research</i> , 2016, 2, 26-37.	0.3	3
97	Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH. <i>Journal of Lipid Research</i> , 2015, 56, 277-285.	2.0	63
98	Fast macromolecular proton fraction mapping of the human liver <i>in vivo</i> for quantitative assessment of hepatic fibrosis. <i>NMR in Biomedicine</i> , 2015, 28, 1716-1725.	1.6	15
99	Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 577-584.	0.8	10
100	Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States. <i>Gastroenterology</i> , 2015, 149, 669-680.	0.6	59
101	Portal Vein Thrombosis Is Not Associated With Increased Mortality Among Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 585-593.	2.4	79
102	Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans Affairs. <i>Epidemiologic Reviews</i> , 2015, 37, 131-143.	1.3	53
103	Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfecting patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 123-129.	0.8	6
104	Prevalence and Management of Chronic Hepatitis C Virus Infection in Women. <i>Medical Clinics of North America</i> , 2015, 99, 575-586.	1.1	6
105	Trends in Burden of Cirrhosis and Hepatocellular Carcinoma by Underlying Liver Disease in US Veterans, 2001-2013. <i>Gastroenterology</i> , 2015, 149, 1471-1482.e5.	0.6	368
106	Improved Surveillance for Hepatocellular Carcinoma With a Primary Care-Oriented Clinical Reminder. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 172-179.	2.4	92
107	Relationship between serum circulating insulin-like growth factor-1 and liver fat in the uninfected states. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 589-596.	1.4	26
108	Similar Effectiveness of Boceprevir and Telaprevir Treatment Regimens for Hepatitis C Virus Infection on the Basis of a Nationwide Study of Veterans. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1371-1380.	2.4	46

#	ARTICLE	IF	CITATIONS
109	Can Computerized Brain Training Games be Used to Identify Early Cognitive Impairment in Cirrhosis?. American Journal of Gastroenterology, 2014, 109, 316-323.	0.2	11
110	Dietary Cholesterol Intake Is Associated With Progression of Liver Disease in Patients With Chronic Hepatitis C: Analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Clinical Gastroenterology and Hepatology, 2013, 11, 1661-1666.e3.	2.4	19
111	Rates and predictors of response to anti-viral treatment for hepatitis C virus in <scp>HIV</scp>/<scp>HCV</scp> co-infection in a nationwide study of 619 patients. Alimentary Pharmacology and Therapeutics, 2013, 38, 1373-1384.	1.9	14
112	Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology, 2013, 57, 81-92.	3.6	219
113	The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology, 2013, 57, 249-257.	3.6	171
114	Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. Journal of Hepatology, 2013, 59, 144-152.	1.8	105
115	Effects of menopause and hormone replacement therapy on the associations of hyperuricemia with mortality. Atherosclerosis, 2013, 226, 220-227.	0.4	27
116	Chronic hepatitis B infection: A global disease requiring global strategies. Hepatology, 2013, 58, 839-843.	3.6	16
117	Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. Journal of Lipid Research, 2013, 54, 1326-1334.	2.0	180
118	Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transplantation, 2013, 19, 634-645.	1.3	143
119	Beyond obesity: Is cholesterol-induced liver injury the cause of non-alcoholic steatohepatitis?. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1412-1414.	1.4	4
120	Are Patients with Child's A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?. American Journal of Transplantation, 2012, 12, 706-717.	2.6	47
121	Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transplantation, 2012, 18, 29-37.	1.3	124
122	Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. Journal of Lipid Research, 2011, 52, 1626-1635.	2.0	196
123	Hepatic Free Cholesterol Accumulates in Obese, Diabetic Mice and Causes Nonalcoholic Steatohepatitis. Gastroenterology, 2011, 141, 1393-1403.e5.	0.6	279
124	Hepatitis B Virus in the United States: Infection, Exposure, and Immunity Rates in a Nationally Representative Survey. Annals of Internal Medicine, 2011, 154, 319.	2.0	142
125	Association between serum uric acid level and chronic liver disease in the United States. Hepatology, 2010, 52, 578-589.	3.6	102
126	Cholelithiasis, Cholecystectomy, and Liver Disease. American Journal of Gastroenterology, 2010, 105, 1364-1373.	0.2	30

#	ARTICLE	IF	CITATIONS
127	Predictors of Early Treatment Discontinuation Among Patients With Genotype 1 Hepatitis C and Implications for Viral Eradication. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 972-978.	2.4	41
128	Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population. <i>Hepatology</i> , 2009, 50, 175-184.	3.6	138
129	Survival after orthotopic liver transplantation: The impact of antibody against hepatitis B core antigen in the donor. <i>Liver Transplantation</i> , 2009, 15, 1343-1350.	1.3	35
130	Is Obesity Associated With Anemia of Chronic Disease? A Population-based Study. <i>Obesity</i> , 2008, 16, 2356-2361.	1.5	141
131	Liver Transplantation for Hepatocellular Carcinoma: Impact of the MELD Allocation System and Predictors of Survival. <i>Gastroenterology</i> , 2008, 134, 1342-1351.	0.6	240
132	Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 938-945.e4.	2.4	234
133	Relationship Between Transferrin-Iron Saturation, Alcohol Consumption, and the Incidence of Cirrhosis and Liver Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 624-629.	2.4	25
134	Survival of Liver Transplant Recipients With Hemochromatosis in the United States. <i>Gastroenterology</i> , 2007, 133, 489-495.	0.6	62
135	Reply: Towards a better liver transplant allocation system. <i>Liver Transplantation</i> , 2007, 13, 937-937.	1.3	0
136	Prevalence and trends of insulin resistance, impaired fasting glucose, and diabetes. <i>Journal of Diabetes and Its Complications</i> , 2007, 21, 363-370.	1.2	59
137	The Prevalence and Predictors of Elevated Serum Aminotransferase Activity in the United States in 1999-2002. <i>American Journal of Gastroenterology</i> , 2006, 101, 76-82.	0.2	286
138	Serum bilirubin and colorectal cancer risk: a population-based cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1637-1642.	1.9	41
139	Serum bilirubin and risk of colorectal cancer: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1259-1261.	1.9	0
140	Bilirubin and colorectal cancer: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1504-1504.	1.9	1
141	Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. <i>Hepatology</i> , 2006, 43, 1145-1151.	3.6	207
142	Development and validation of a model predicting graft survival after liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 1594-1606.	1.3	117
143	Is <i>Helicobacter pylori</i> seropositivity related to body mass index in the United States?. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 765-772.	1.9	52
144	Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 67-74.	2.4	283

#	ARTICLE	IF	CITATIONS
145	Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. <i>Gastroenterology</i> , 2005, 128, 627-635.	0.6	68
146	The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. <i>Gastroenterology</i> , 2004, 126, 1293-1301.	0.6	182
147	Racial differences in the relationship between hepatitis C infection and iron stores. <i>Hepatology</i> , 2003, 37, 795-801.	3.6	51
148	Terlipressin in acute oesophageal variceal haemorrhage. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 53-64.	1.9	153
149	Is obesity a risk factor for cirrhosis-related death or hospitalization? a population-based cohort study. <i>Gastroenterology</i> , 2003, 125, 1053-1059.	0.6	107
150	Iron deficiency and gastrointestinal malignancy: a population-based cohort study. <i>American Journal of Medicine</i> , 2002, 113, 276-280.	0.6	115
151	Prospective evaluation of a clinical guideline for the diagnosis and management of iron deficiency anemia. <i>American Journal of Medicine</i> , 2002, 113, 281-287.	0.6	57